SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-007378
Filing Date
2024-02-28
Accepted
2024-02-28 06:35:25
Documents
21
Period of Report
2024-02-28
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20240228.htm   iXBRL 8-K 27916
2 EX-99.1 pressrelease-4q23financi.htm EX-99.1 19054
6 pressrelease-4q23financi001.jpg GRAPHIC 211057
7 pressrelease-4q23financi002.jpg GRAPHIC 251595
8 pressrelease-4q23financi003.jpg GRAPHIC 269875
9 pressrelease-4q23financi004.jpg GRAPHIC 157646
10 pressrelease-4q23financi005.jpg GRAPHIC 193263
11 pressrelease-4q23financi006.jpg GRAPHIC 157856
  Complete submission text file 0001628280-24-007378.txt   1895090

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20240228.xsd EX-101.SCH 1922
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20240228_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20240228_pre.xml EX-101.PRE 13060
22 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20240228_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 24690078
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)